U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT03836833) titled 'Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation' on Dec. 13, 2018.
Brief Summary: A phase I/II, open label, randomized crossover pharmacokinetic, safety and acceptability study of the Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination vs. Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg tablets) in HIV infected Children.
The study is intended to support the adoption of the 4-in-1 by healthcare providers and will provide data that may support its registration in certain countries. The study will be carried out in HIV-infected children in Uga...